Intravenous Vitamin C in the Treatment of Viral Infection, Especially in the Treatment of Shingles

NCT00921934 | Completed Results

• 1 other identifier: 168 A 08 VC
• Study Type: observational
• Target: 68
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic viral infections induce oxidative stress that can cause a number of concomitant diseases, e.g. cardio-vascular diseases or metabolic disorders. Therefore, a sufficient treatment of oxidative stress may be of benefit for the patient to prevent further diseases. Shingles (herpes zoster infection) have been successfully treated with antioxidative substances like high-dose vitamin C for ages. Not only the acute symptoms can be diminished by high-dose vitamin C. Even long-term sequelae, like painful post-herpetic neuropathy, may be mitigated or even fully avoided.

Conditions

Virus Diseases; Herpes Zoster

Keywords

Herpes; Shingles; virus disease; vitamin C; ascorbic acid; antioxidant; oxidative stress

Outcome Measures

Primary Outcomes (1)

• Change of Pain Measured by VAS

  VAS (minimum = 0 = no pain, maximum = 10 = extrem pain, change of pain measured by VAS

  visit 1 - 3

Study Arms (1)

Vitamin C

Adult patients suffering from acute viral infection, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany, and who are treated with standard therapy and add-on vitamin C.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Cohort of adult patients suffering from acute viral infections, especially herpes zoster, presenting themselves in Primary Care Centers or hospitals all over Germany.

You may not qualify if:

• Observational Criteria:
• adult patients
• acute viral infection (especially herpes zoster)
• Primary Care patient
• eligible for add-on therapy with vitamin C
• willingness to provide pseudonymized data to the Sponsor

Sponsors & Collaborators

• Pascoe Pharmazeutische Praeparate GmbH: lead
• Dr. Loges & Co. GmbH: collaborator

Study Sites (1)

Praxis Dr. Schencking, Rheinstr. 77a

Ransbach-Baumbach, Rhineland-Palatinate, 56235, Germany

Location

MeSH Terms

Conditions

Virus Diseases; Herpes Zoster; Herpes Simplex

Condition Hierarchy (Ancestors)

Infections; Varicella Zoster Virus Infection; Herpesviridae Infections; DNA Virus Infections; Skin Diseases, Viral; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases

Results Point of Contact

• Title: Dr. med. Martin Schencking
• Organization: Department for Complementary and Alternative Medicine

+0049-2602-684-614

Study Officials

• Martin Schencking, MD

  Rheinstr. 77a, D-56235 Ransbach-Baumbach

  PRINCIPAL INVESTIGATOR

• Bianka Krick

  Pascoe Pharmazeutische Praeparate GmbH

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 16, 2009
• First Posted: June 17, 2009
• Study Start: April 1, 2009
• Primary Completion: December 1, 2010
• Study Completion: December 1, 2010
• Last Updated: December 21, 2017
• Results First Posted: October 26, 2012

Record last verified: 2017-11

Locations

DE (1)